70 Quick summary: Oncologists have identified a specific structural protein variation termed CLASS 3G that explains why a quarter of lung cancer patients with common genetic mutations fail to benefit from standard targeted therapies. Clinical tracking showed that individuals carrying this structural subtype suffer disease progression twice as fast under standard single drug treatments, though initiating a combined targeted and chemotherapy regimen more than doubles their progression free survival time. These breakthrough findings carry major implications for public policy and healthcare practice by providing a precise new biomarker that can steer frontline clinical decisions away from ineffective protocols, directly improving patient well-being while protecting vulnerable individuals from the unnecessary toxicity of trial and error medicine. A new study has identified why some lung cancer patients with common EGFR mutations respond poorly to standard targeted therapies, offering a potential route to more effective, personalised first-line treatment. For many patients with Non-Small-Cell Lung Cancer (NSCLC), mutations in the EGFR gene make their tumours highly sensitive to targeted drugs known as tyrosine kinase inhibitors (TKIs). EGFR exon 19 deletions are among the most common sensitising alterations, typically predicting good responses to drugs such as osimertinib. Yet about a quarter of patients with these deletions see limited benefit. Researchers from the National Cancer Center, Chinese Academy of Medical Sciences, have pinpointed the reason in the precise three-dimensional architecture of the mutated protein. Publishing their findings in Science China Life Sciences, the team developed a structure-based classification for EGFR exon 19 deletion mutations and identified a distinct subgroup termed CLASS 3G. This subtype alters the protein shape in a way that reduces how effectively third-generation targeted drugs like osimertinib can bind. “Think of the drug as a key and the mutated protein as a lock,” explained Dr Wei Zhuang. “Most mutations are similar locks that the key fits well. But CLASS 3G alters the lock just enough that the key doesn’t turn as smoothly, weakening the treatment’s effect.” This structural difference has clear consequences for patients. In clinical cohorts analysed by the researchers, those with CLASS 3G mutations experienced cancer progression in roughly half the time on third-generation drug monotherapy compared with patients who had other subtypes. Median progression-free survival in the first-line setting with third-generation TKIs was 12.8 months versus 25.6 months, while in the second-line setting it was 7.7 months versus 15.2 months. These findings were validated in an independent cohort. The study also points to a practical solution. For patients with the CLASS 3G subtype, starting treatment with a combination of the targeted drug plus chemotherapy more than doubled the time before disease progression, extending median progression-free survival to 32.5 months compared with 12.8 months for targeted therapy alone. EGFR mutations occur in approximately 10%–15% of NSCLC cases in Western populations and up to 30%– 50% in Asian populations, with exon 19 deletions accounting for a substantial proportion of these. Osimertinib is currently a standard first-line option for eligible patients, and recent trials have also supported combining it with platinum-based chemotherapy in broader EGFR-mutated advanced NSCLC to improve outcomes. “This moves us beyond just finding the mutation to understanding its functional consequence,” says Dr Zhuang. “By reading the structural fine print of the mutation, we can better match patients to the most effective strategy from day one.” The classification relied on molecular docking analysis and was linked to both laboratory binding studies and real-world patient outcomes across 2 cancer centres, involving 399 patients with 35 distinct EGFR exon 19 deletion variants. Lung cancer remains one of the leading causes of cancer death worldwide. While targeted therapies have transformed care for those with driver mutations, resistance and variable responses continue to challenge clinicians. Tools that refine patient selection, such as this structure-based approach, could help optimise first-line decisions and potentially improve survival while minimising unnecessary toxicity from broader treatments. Experts note that broader adoption of detailed molecular profiling, including next-generation sequencing, already helps identify EGFR alterations. Incorporating structural classification could add another layer of precision, particularly for the subset of patients whose tumours fall into the CLASS 3G category. The researchers emphasise that their findings provide a potential biomarker to guide personalised treatment, though further prospective studies will be needed to confirm how best to integrate this classification into routine clinical practice.